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Postoperative Irradiation for Rectal Cancer Increases the
Risk of Small Bowel Obstruction After Surgery
Nancy N. Baxter, MD, PhD,*† Lacey K. Hartman, MPP,‡ Joel E. Tepper, MD,
Rocco Ricciardi, MD,¶ Sara B. Durham, MSc,‡ and Beth A. Virnig, PhD, MPH‡§
Objective: To determine the risk of small bowel obstruction (SBO)
after irradiation (RT) for rectal cancer
Background: SBO is a frequent complication after standard resec-
tion of rectal cancer. Although the use of RT is increasing, the effect
of RT on risk of SBO is unknown.
Methods: We conducted a retrospective cohort study using Surveil-
lance, Epidemiology, and End Results cancer registry data linked to
Medicare claims data to determine the effect of RT on risk of SBO.
Patients 65 years of age and older diagnosed with nonmetastatic
invasive rectal cancer treated with standard resection from 1986
through 1999 were included. We determined whether patients had
undergone RT and evaluated the effect of RT and timing of RT on
the incidence of admission to hospital for SBO, adjusting for
potential confounders using a proportional hazards model.
Results: We identified a total of 5606 patients who met our selection
criteria: 1994 (36%) underwent RT, 74% postoperatively. Patients
were followed for a mean of 3.8 years. A total of 614 patients were
admitted for SBO over the study period; 15% of patients in the RT
group and 9% of patients in the nonirradiated group (P  0.001).
After controlling for age, sex, race, diagnosis year, type of surgery,
and stage, we found that patients who underwent postoperative RT
were at higher risk of SBO, hazard ratio 1.69 (95% CI, 1.3–2.1).
However, the long-term risk associated with preoperative irradiation
was not statistically significant (hazard ratio, 0.89; 95% CI, 0.55–
1.46).
Conclusions: Postoperative but not preoperative RT after standard
resection of rectal cancer results in an increased risk of SBO over
time.
(Ann Surg 2007;245: 553–559)
In 1990, the National Institutes of Health Consensus Con-ference established adjuvant postoperative radiation ther-
apy, along with chemotherapy, as the standard of care for
achieving regional control of stage II and III rectal cancer
after surgical resection in the United States.1 Numerous
studies have substantiated the benefits of adjuvant radiation
therapy for preventing local recurrence in patients with rectal
cancer2–5; thus, radiation therapy is commonly used in the
United States. In a previous population-based study using
SEER data, we found that, in the year 2000, 59% of patients
with AJCC stage II rectal cancer and 68% with AJCC III
rectal cancer underwent irradiation,6 and this rate was in-
creasing substantially over time. With mounting evidence of
the superiority of preoperative irradiation,7 the proportion of
patients undergoing preoperative versus postoperative radia-
tion therapy has also increased.
During radiation therapy, a significant amount of small
bowel may lie in the irradiated field and receive a substantial
radiation dose. Indeed, acute small bowel toxicity is one of
the more common dose-limiting toxicities of irradiation for
rectal cancer.8 Chronic gastrointestinal symptoms after treat-
ment of rectal cancer are common9,10; however, in many
cases, it is difficult to attribute problems to any specific aspect
of care (surgery, chemotherapy, or irradiation). For example,
small bowel obstruction (SBO) after major abdominal sur-
gery is a frequent occurrence.11 Therefore, it may be difficult
to determine if RT results in an increased risk above baseline.
While there is some evidence that there may be less small
bowel toxicity with preoperative irradiation,12 the data are
primarily based on short-course irradiation (with limited
generalizability to most North American centers) and without
concurrent chemotherapy. We therefore designed this study
to determine if irradiation is associated with an increased rate
of SBO in patients with resectable rectal cancer, and to
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evaluate other factors (particularly type of surgery and timing
of irradiation) that might influence the relationship.
MATERIALS AND METHODS
Data
We used Surveillance, Epidemiology, and End Results
(SEER) cancer registry data linked to Medicare enrollment
records and utilization data (SEER-Medicare). SEER, a pop-
ulation-based cancer registry sponsored by the National Can-
cer Institute, collects information on cancer incidence and
survival from 11 population-based cancer registries; these 11
registries include about 14% of the U.S. population.13 The
information collected by SEER includes patient characteris-
tics, primary tumor site, tumor stage, first course of treatment
(including surgery and irradiation), timing of irradiation,
follow-up for vital status, and cause of death as recorded on
the death certificate.13
Medicare provides comprehensive health care for about
98% of the U.S. population age 65 or older. Cancer cases
reported to SEER have been matched to the Medicare master
enrollment file, to facilitate population-based health services
research. Medicare eligibility has been identified for 94% of
people 65 or older identified by SEER.14 For Medicare
enrollees who do not participate in a managed care plan,
claims data for hospitalizations are available through the
Medicare Provider Analysis and Review (MedPAR) file.
SEER-Medicare includes cancer cases reported to SEER
from 1973 through 1999 and all Medicare claims for people
diagnosed with cancer from 1991 through 2001. Hospitaliza-
tion data (per the MedPAR file) are available from 1986
through 2001. For this study, we evaluated only hospitaliza-
tion for SBO and therefore were able to determine the rate of
admission for SBO since 1986.
Patients
Included in our study were patients age 65 or older who
were diagnosed with invasive, nonmetastatic rectal cancer
from January 1, 1986, through December 31, 1999. We
included only patients who underwent radical resection of
rectal cancer (SEER site-specific surgery 30 through 90) for
the first course of treatment.
Excluded from our study were patients with a previous
cancer diagnosis and patients who developed a second can-
cer; patients with in situ, metastatic, or unstaged cancers;
patients whose cancer was diagnosed by autopsy or first cited
on the death certificate; patients who did not undergo surgery,
or had local excision only; patients whose radiation status
was unknown or who received only radioactive implants,
radioisotopes, or other forms of radiation besides conven-
tional therapy; patients who were enrolled in a managed care
organization any time from 6 months prior to cancer diagno-
sis (because Medicare files do not include insurance claims
data on managed care enrollees); patients whose race was
unknown; and patients who presented with the diagnosis of
SBO at the time of cancer diagnosis or within the month
following diagnosis. Cause of death is available from SEER
to December 31, 2000; therefore, this was considered the last
date of potential follow-up for the purposes of this study.
Analysis
SEER routinely collects data on the first course of
treatment, including radiation therapy. For our study, patients
who underwent external-beam irradiation were defined as the
irradiated group. The nonirradiated group was defined as
patients who were prescribed no radiation therapy or refused
such treatment. We also determined if irradiation was deliv-
ered before surgery (preoperative irradiation) or after surgery
(postoperative irradiation). SBO was defined from the Med-
PAR data from 1986 through 2000 using the International
Classification of Disease 9 (ICD-9) code15 560 (intestinal
obstruction without mention of hernia). For patients admitted
with a diagnosis of SBO, we determined if further episodes
developed over time, if surgery was performed during the
admission, and assessed vital status at discharge for each
episode.
We compared demographic variables between the irra-
diated and nonirradiated groups, using the 2 test for cate-
gorical variables, the Student t test for continuous normally
distributed variables, and the Wilcoxon rank sum test for
continuous variables that were not normally distributed. We
calculated Kaplan-Meier curves representing the time from
cancer diagnosis to SBO, and compared the curves using the
Wilcoxon method. We compared the irradiated groups to the
nonirradiated group and also compared the preoperative,
postoperative, and nonirradiated groups. To control for po-
tential confounders, we constructed a proportional hazards
model to evaluate the relationship between irradiation and
SBO, adjusting for age at cancer diagnosis (in 5-year incre-
ments), sex, race (black vs. non-black), type of surgery
(abdominoperineal resection APR vs. other radical surgery
non-APR) stage of disease (local or regional stage), SEER
registry, and time period of diagnosis (1986–1990, 1991–
1995, and 1996–1999). We tested the model for possible
interaction effects between irradiation and stage of disease,
race, age, type of surgery, and time period of diagnosis.
Follow-up was calculated as the time between diagnosis and
admission for SBO. Censoring events included patient death,
survival after 12 years of follow-up, and end of follow-up
(December 31, 2000).
Because our study used preexisting data with no per-
sonal identifiers, the Human Subjects Committee of the
University of Minnesota’s Institutional Review Board deter-
mined that it was exempt from review. We performed the
statistical analysis using SAS version 9.1. All statistical tests
were 2 sided, and we considered a P value of less than 0.05
to be statistically significant. In the past, we used similar
methodology successfully to evaluate the effect of irradiation
on the risk of pelvic fracture in older women with pelvic
malignancies.16
RESULTS
A total of 5606 patients met our study’s selection
criteria. Patient characteristics are summarized in Table 1. Of
these 5606 patients 1994 (35.6%) underwent radiation ther-
apy (irradiated group) and 3612 (64.4%) did not (nonirradi-
ated group). The majority of patients undergoing irradiation
did so in a postoperative fashion (73.6%). We could not
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determine timing of irradiation in 102 (5%) patients under-
going RT.
The average age at diagnosis was 75.2 years. Patients in
the irradiated group were slightly younger (average, 73.2
years) than patients in the nonirradiated group (average, 76.4
years) (P  0.001). Mean follow-up time for the entire cohort
was 3.8 years. Mean follow-up time was slightly greater for
the nonirradiated group (4.0 years) than the irradiated group
(3.5 years) (P  0.001), potentially because proportionately
fewer patients were treated with RT in the early time period
(28.6% of patients treated with RT, 1986–1990) than in the
later time period (33.3% of patients, 1996–1999) (P 
0.001), consistent with the known increase in the use of RT
in the treatment of rectal cancer during the timeframe of the
study.6 In addition, patients in the irradiated group were more
likely to have been diagnosed with regional stage of disease
(75.6%) than patients in the nonirradiated group (39.9%)
(P  0.001).
A total of 614 patients (11%) were admitted with a
primary diagnosis of SBO over the study period. The cumu-
lative incidence of hospital admission for SBO was greater in
the irradiated group than in the nonirradiated group (Fig. 1).
The cumulative incidence of SBO at 5 years was 18% in the
irradiated group versus 11% in the nonirradiated group. For
those undergoing preoperative irradiation (n  425), the
cumulative risk of SBO at 5 years was 14% as compared with
20% in those undergoing postoperative irradiation. However,
from the Kaplan-Meier curve (Fig. 2), the risk of SBO in the
preoperative irradiation and postoperative irradiation groups
was similar for the first 12 months; thereafter, the risk of SBO
in the group undergoing preoperative irradiation was similar
to the risk in patients not undergoing irradiation. Of note,
patients undergoing preoperative irradiation had a mean fol-
low-up of only 2.9 years (most patients undergoing preoper-
ative irradiation were diagnosed after 1996).
We used a proportional hazards model to evaluate the
influence of radiation therapy on incidence of admission for
SBO (Table 2). After controlling for other factors, we found
that patients undergoing irradiation had a higher risk of
admission for SBO over time than patients who did not
undergo irradiation (hazard ratio associated with irradiation 
1.53; 95% confidence interval, 1.28–1.83). Being black and
having regional (vs. local) cancer also increased risk of SBO.
However, we found no statistically significant interaction
effects between these factors and radiation status on risk of
admission for SBO over time. Type of surgery (APR vs. other
radical resection) did not influence the risk of SBO.
Because there was evidence of violation of the propor-
tional hazards assumption for patients undergoing preopera-
tive irradiation (with a change in risk after 12 months) to
evaluate the long-term effect of timing of irradiation, we
repeated our proportional hazards model starting 12 months
after diagnosis. To evaluate the short-term effect, we per-
formed a logistic regression comparing the proportion of
patients developing an SBO in the first year between the 3
groups. After adjusting for other covariates, within the first 12
months of diagnosis patients who underwent postoperative
irradiation were statistically significantly more likely to have
an admission for SBO than patients who did not undergo
irradiation (odds ratio  1.83; 95% CI, 1.30–2.58). Patients
undergoing preoperative irradiation were also more likely to
have an admission for SBO within the first 12 months of
diagnosis than patients who did not undergo irradiation,
although this did not achieve statistical significance (OR 
1.59; 95% CI, 0.95–2.67). In our proportional hazards model,
preoperative irradiation was not associated with an increased
TABLE 1. Patient Characteristics
Variable Category All Patients
Nonirradiated
Group Irradiated Group P
Total patients (% irradiated) 5606 3612 (64.4%) 1994 (35.6%) NA
Age at diagnosis (yr) 65–69 1313 (47.1%) 694 (19.2%) 619 (31.0%) 0.0001
70–74 1505 (42.3%) 869 (24.1%) 636 (31.9%)
75–79 1313 (34.5%) 860 (23.8%) 453 (22.7%)
80 1475 (19.4%) 1189 (32.9%) 286 (14.3%)
Mean age (yr) at diagnosis 75.2 76.4 73.2 0.0001
Year at diagnosis 1986–1990 1902 (30.0%) 1331 (36.9%) 571 (28.6%) 0.0001
1991–1995 2072 (36.6%) 1313 (36.4%) 759 (38.1%)
1996 1632 (40.7%) 968 (26.8%) 664 (33.3%)
Race Non-Black 5.379 (35.7%) 3457 (95.7%) 1922 (96.4%) 0.22
Black 227 (31.7%) 155 (4.3%) 72 (3.6%)
Stage Localized 2659 (18.3%) 2172 (60.1%) 487 (24.4%) 0.0001
Regional 2947 (51.1%) 1440 (39.9%) 1507 (75.6%)
Type of surgery APR 3146 (32.0%) 2138 (59.2%) 1008 (50.5%) 0.0001
Non-APR 2460 (40.1%) 1474 (40.8%) 986 (49.5%)
Mean follow-up (yr) (SD) 3.8 (3.2) 4.0 (3.4) 3.5 (2.9) 0.0001
Small bowel obstruction Yes 614 (48.5%) 316 (8.8%) 298 (14.9%) 0.0001
No 4992 (34.0%) 3296 (91.2%) 1696 (85.1%)
NA indicates not applicable.
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risk of SBO more than 12 months after diagnosis (HR 
0.89; 95% CI, 0.55–1.46) (Table 3). However, postoperative
irradiation was associated with a statistically significant long-
term risk of SBO (HR  1.69; 95% CI, 1.34–2.14).
Of the 578 patients who survived their first admission
for SBO, 156 (25.4% of patients admitted for SBO) were
admitted for a second obstruction during the study period. In
the irradiated group, 78 patients required at least 2 admissions
for SBO (3.9% of total cohort) versus 78 patients in the
nonirradiated group (2.2% of total cohort) (P  0.001),
although for the 578 patients surviving their first admission
for SBO, irradiation did not increase the likelihood of recur-
rence (27.8% of patients admitted for SBO in the irradiated
group experienced recurrence vs. 26.3% of patients in the
nonirradiated group, P  0.71). A total of 249 patients
required surgery for SBO during admission, 6.6% of all
patients in the irradiated group and 3.2% of all patients in the
nonirradiated group (P  0.001). Of the 614 patients who had
an admission for SBO in the study period, 8.1% (n  50) died
during admission. There was no significant difference in rates
of mortality from small bowel obstruction by irradiation
status (P  0.10).
Patients undergoing irradiation were more likely to
have regional stage disease than those not undergoing irradi-
ation and thus were at a higher risk of cancer recurrence. As
peritoneal recurrence can present with bowel obstruction, we
were concerned about the risk of residual confounding. We
therefore repeated our analysis excluding all patients (n 
1754) who died of colorectal cancer in the study period and
found no substantive differences (data not shown).
DISCUSSION
With greater awareness of the benefits of adjuvant
irradiation for patients with rectal cancer, the number of
rectal cancer patients treated in this fashion has dramatically
increased.6 However, given that treatment is delivered with a
curative intent, it is essential that long-term consequences for
survivors are fully understood and, where possible, that
factors modifying risk are identified. Our population-based,
retrospective cohort study demonstrates that irradiation is
associated with an increased risk of SBO for patients treated
with radical resection of rectal cancer. Consistent with pre-
vious literature,17 we found that SBO is a frequent compli-
cation of surgery for rectal cancer; the risk of admission for
SBO within 5 years of rectal cancer diagnosis was 11% in our
surgery only group. However, because of the high baseline
risk, the hazard ratio associated with irradiation (1.5) resulted
FIGURE 1. Time from rectal cancer diagnosis to small bowel obstruction. Irradiated group is represented by the broken line;
nonirradiated group, solid line.
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in a clinically significant increase in the cumulative incidence
of SBO in patients undergoing postoperative irradiation over
time. Bowel obstruction as a long term complication of
irradiation has been well described; the risk increases when
substantial amounts of small bowel are included in the irra-
diation field, particularly when doses above 50 to 55 Gy are
delivered.8 Small bowel exposed to a significant dose of
irradiation can, in the long term, develop fibrosis and isch-
emia that may manifest as SBO. However, the reported rates
for SBO after pelvic irradiation vary widely and can be
difficult to interpret; SBO and diarrhea as measures of long-
term small bowel toxicity are often combined into a single
measure of toxicity when clinical trials are reported. SBO can
be a serious complication; in our study, 32% of patients
developing SBO required surgery, and 25% had multiple
admissions for SBO. In addition, 8.1% of patients admitted
for SBO died during admission.
While demonstrating and quantifying an increased risk
of SBO with irradiation, our study also found that timing of
irradiation modified SBO risk. Within the first year, patients
undergoing preoperative irradiation had a higher risk of SBO
than those not undergoing irradiation (although this increase
was not statistically significant). However, after the first year,
the risk of SBO was similar between these groups and was
substantially lower than in patients undergoing postoperative
irradiation. Adhesions commonly form after pelvic surgery,
and this may lead to fixation of small bowel loops in the
pelvis. Green et al18,19 found that 65% of patients referred for
postoperative irradiation had fixed loops of small bowel
within the pelvis as compared with 18% of patients with no
prior surgery. Bowel that is fixed in the pelvis is more likely
to receive a significant cumulative dose of irradiation than
mobile bowel, as fixed bowel will maintain the same position
in the pelvis over the course of treatment. However, most
FIGURE 2. Time from rectal cancer diagnosis to small bowel obstruction, evaluating sequence of irradiation and surgery (*).
Irradiated group-postoperative sequence is represented by the broken line; irradiated group-preoperative sequence, dotted
line; nonirradiated group, solid line. *A total of 102 patients (2.0% of total cohort) were excluded as sequence of irradiation
and surgery was unknown.
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patients treated with preoperative irradiation in our study
were diagnosed after 1996; and although we controlled for
time period, it is possible that the substantial improvements in
irradiation technique that have occurred over time may have
confounded our results.
Our findings are consistent with the results of recent
randomized control trials of preoperative irradiation. In the
Dutch trial of total mesorectal excision with and without
short-course preoperative irradiation,3,12 11% of patients in
the surgery only group and 11% of patients in the surgery
with irradiation group were admitted with a diagnosis of SBO
over a median follow-up of 5.1 years, indicating no increased
risk of SBO in patients treated with short course preoperative
irradiation. In the German trial comparing preoperative irra-
diation to postoperative irradiation for advanced rectal can-
cer,7 long-term gastrointestinal side effects of irradiation
(chronic diarrhea or obstruction as a combined outcome)
occurred in 9% of patients undergoing preoperative treatment
as compared with 15% of patients undergoing postoperative
irradiation. Similar to these findings, the results of our study
reinforce the superiority of preoperative therapy in terms of
reducing the long-term risk of SBO.
Our study used cancer registry and administrative data
and therefore has several limitations. We did not have infor-
mation about irradiation dosage or fields, and we had no
information about the use of techniques to minimize irradia-
tion exposure of small bowel, such as positioning or the use
of belly boards, and the use of such techniques may have
increased over time. However, because SEER is population-
based, our patients would have received the standard care for
their communities. We did not evaluate the use of chemo-
therapy. It is possible that the use of chemosensitization with
irradiation may increase the susceptibility of small bowel to
acute and/or chronic toxicity and, therefore, some of the
effect of irradiation demonstrated in our study may be due to
the combination of chemotherapy and irradiation. Not all
patients in our study would have received chemosensitiza-
tion; thus, given the current North American standard of
care,20 our results may underestimate the risk of SBO with
treatment in the present era. We found that stage was asso-
ciated with the risk of SBO; patients with a more advanced
stage of disease were more likely to develop SBO. While it is
possible that the finding of more advanced cancer might alter
surgical management in ways that could affect the risk of
SBO, patients who received postoperative RT were at in-
creased risk of SBO irrespective of stage of disease.
Because our study relied on observational data, rather
than on the results of a randomized trial, the potential for
patient selection bias, although small, remains. For example,
we did not evaluate prior surgery, a known risk factor for
SBO; however, prior surgery should not have resulted in
differential treatment selection. In addition, our study was
restricted to the elderly, and it is possible that irradiation may
have a differential effect in younger patients. However, it is
unlikely that the limitations of our study would have altered
our final conclusions: namely, that postoperative irradiation,
but not preoperative irradiation, for rectal cancer in older
patients results in an increased risk of SBO over time. Our
study provides further evidence of the superiority of preop-
erative irradiation and supports a continued change of prac-
tice to the use of this method when adjuvant irradiation for
rectal cancer is needed.
TABLE 3. Proportional Hazards Model Predicting Time to






Surgery only (nonirradiated) 1.0 (referent) 0.0001
Surgery  postoperative irradiation 1.69 (1.34–2.14)
Surgery  preoperative irradiation 0.89 (0.55–1.46)
Age (yr) at diagnosis
5-yr intervals (65–69 through 85) 0.98 (0.90–1.07) 0.60
Stage
Regional 1.0 (referent) 0.0001
Localized 0.55 (0.43–0.68)
Race
Black 1.71 (1.08–2.70) 0.02
Non-Black 1.0
Sex
Male 1.09 (0.89–1.33) 0.42
Female 1.0
Type of surgery
APR 0.92 (0.75–1.12) 0.40
Non-APR 1.0
*Adjusted for registry, time period of diagnosis, and all other factors in the model.
†A total of 102 patients (2.0% of total cohort) excluded as sequence of irradiation
and surgery was unknown.
TABLE 2. Proportional Hazards Model Predicting Time to





Surgery only group (nonirradiated) 1.0 (referent) 0.0001
Irradiated group 1.53 (1.28–1.83)
Age (yr) at diagnosis
5-yr intervals (65–69 through 85) 0.99 (0.92–1.06) 0.74
Stage
Regional 1.0 (referent) 0.0001
Localized 0.59 (0.49–0.71)
Race
Black 1.51 (1.04–2.18) 0.03
Non-Black 1.0
Sex
Male 1.01 (0.86–1.18) 0.95
Female 1.0
Type of surgery
APR 1.02 (0.87–1.20) 0.78
Non-APR 1.0
*Adjusted for registry, time period of diagnosis, and all other factors in the model.
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